Un­fazed by re­cent car­dio set­backs, No­var­tis takes an­oth­er PhI­II chal­lenge head-on with Akcea drug

In the lat­est move of its long wres­tle with the gi­ant car­dio mar­ket, No­var­tis is mount­ing a late-stage cam­paign for a lipopro­tein(a)-low­er­ing drug de­vel­oped by Akcea.

The phar­ma gi­ant is go­ing for an op­tion to take over Phase III de­vel­op­ment three months af­ter the close­ly held Io­n­is af­fil­i­ate un­veiled Phase II da­ta that showed its drug, then called AKCEA-APO(a)-LRx, could slash Lp(a) lev­els sig­nif­i­cant­ly in at-risk car­dio pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER